Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0377-4929.155345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Remission With Allo-HSCT for t(1;8)(q25;p11) Translocation: A Rare Case Report and Literature Review.
Transplant Proc
November 2024
Department of Hematology, Hainan General Hospital, Haikou, Hainan Province, China. Electronic address:
Background: The 8p11 myeloproliferative syndrome (EMS), a rare disorder characterized by translocations and interchanges at chromosome 8p11, is usually refractory to chemotherapy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only promising treatment for long-term remission. Among 14 translocation partners associated with EMS, t(1;8)(q25;p11) are very uncommon, with only four cases previously reported in peer-reviewed journals in English.
Case Presentation: Here we report a 43-year-old man who presented with atypical peripheral T-cell lymphomas.
Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement t(8;13)(p11;q12): A case report and literature review.
Oncol Lett
October 2024
Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
8p11 myeloproliferative syndrome (EMS) is a rare and aggressive hematological malignancy, characterized by myeloproliferative neoplasms, and associated with eosinophilia and T- or B-cell lineage lymphoblastic lymphoma. The pathogenesis is defined by the presence of chromosomal translocations associated with the fibroblast growth factor-1 () gene, located in the 8p11-12.1 chromosomal locus.
View Article and Find Full Text PDFCase Report: A novel fusion in acute B-lymphoblastic leukemia identified by RNA sequencing.
Front Oncol
November 2023
Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
8p11 myeloproliferative syndrome is a rare hematological malignancy with aggressive course caused by the various translocation of . In this study, a novel fusion was identified by RNA sequencing in a 28-year-old male patient with acute B-lymphoblastic leukemia. The patient harbors an in-frame fusion between exon 15 and exon 10.
View Article and Find Full Text PDFMyeloid/lymphoid neoplasm with a novel cryptic rearrangement presenting as de novo acute leukemias.
Leuk Lymphoma
December 2023
Northwell Health, Greenvale, NY, USA.
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).
Int J Hematol
September 2023
Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
8p11 myeloproliferative syndrome is a rare hematological malignancy caused by the translocation of FGFR1. Patients present with a myeloproliferative neoplasm that frequently transforms into acute myeloid leukemia or T-lymphoblastic lymphoma/leukemia. Here, we report a molecular study of a patient with 8p11 myeloproliferative syndrome who developed acute B-lymphoblastic leukemia and then transformed to mixed-phenotype acute leukemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!